July 2024 Pharmacy Policy Updates
Review July 2024 pharmacy policy updates for MVP plans, including new drug policies, updated coverage guidelines, and changes to Part B medications and specialty therapies.
Effective April 1, 2024
|
Pharmaceutical Policy Name |
Status |
|---|---|
|
Spesolimab Part B |
Reviewed/No Changes |
|
Duchenne Muscular Dystrophy |
Updated |
|
Medicare Part B Step Therapy |
Updated |
|
Quantity Limits for Prescription Drugs |
Updated |
|
Cystic Fibrosis (Select Oral Agents) |
Updated |
|
Izervay |
New Policy |
|
Izervay Part B |
New Policy |
|
Xolair |
Updated |
Effective June 1, 2024
|
Pharmaceutical Policy Name |
Status |
|---|---|
|
Pharmaceutical Policy Name |
Status |
|
Baricitinib |
New Policy |
|
Cosmetic Drug Agents |
Updated |
|
Valchlor |
Reviewed/No Changes |
|
Onychomycosis |
Updated |
|
Luxturna |
Reviewed/No Changes |
|
Luxturna Part B |
Reviewed/No Changes |
|
Parsabiv |
Updated |
|
Spesolimab |
Reviewed/No Changes |
|
Immunoglobulin Therapy |
Updated |
|
Immunoglobulin Therapy Part B |
Updated |
|
Growth Hormone Therapy |
Updated |
|
Xolair Medicare Part B |
Updated |
|
Dupixent |
Updated |
|
Diclofenac (topical) |
Updated |
|
Topical Agents for Pruritus |
Updated |
|
Ritlecitinib |
New Policy |
Policy Updates
Review other articles in this issue regarding formulary, pharmacy policy, and medical policy updates.